On the RECORD: Rosiglitazone Safer Than Previously Thought

Anne L. Peters, MD, CDE, FACP


July 02, 2009

This feature requires the newest version of Flash. You can download it here.

Citation: Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009 Jun 5. [Epub ahead of print]. Available at Accessed June 22, 2009.